Shots: In Jul 2020, following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care […]readmore
Shots: Lupin has launched favipiravir in India under the brand name ‘Covihalt’ for the treatment of mild to moderate COVID-19 Covihalt will be available as 200mg tablets in the form […]readmore
Shots: Cadila to strengthen its biosimilar portfolio and oncology footprints in India with the launch of Ritucad and has cleared USFDA inspection in Feb’20 Additionally, the company has launched its […]readmore
Shots: Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of Rs. 39/tablet Cipla receives the DCGI approval for Ciplenza […]readmore
Shots: Cadila plans to launch multiple biosimilars including Bevaro in 2020 which are safe and efficacious compared to conventional treatment medicine has cleared The company has also cleared he USFDA […]readmore
Shots: UK Rapid Test Consortium’s (UK-RTC) finger prick test passes its first major trial that delivers results in 20mints. and demonstrate 98.6% accuracy in its clinical study. The AbC-19 lateral […]readmore
Shots: The launch of Bayer-MassCONNECT Asia will support the startup community in Asia with a special focus on China. The collaboration of two companies will integrate MassBio’s mentoring expertise with […]readmore
Shots: Celltrion has completed the development of a point-of-care antigen testing kit for COVID-19 in collaboration with BBB. The POCT kit is a portable and overly sensitive device for use […]readmore
Shots: Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada Sandoz has received Health Canada’s Notice of Compliance on Apr […]readmore
Shots: Celltrion in collaboration with Poonglim Pharmatech will accelerate the development of its insulin pen biosimilar. The company will initiate the development of the insulin biosimilar in 2020 with an […]readmore
Copyright © 2020 Digiqole. All Right Reserved.